Rabbit antibody to GFAP (250-300)

FUNCTION: GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.
Defects in GFAP are a cause of Alexander disease (ALEXD). Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course.
SUBCELLULAR LOCATION: Cytoplasm. Note: Associated with intermediate filaments
Tissue expression: Expressed in the cortex and hippocampus. Expression decreases following acute and chronic corticosterone treatment; expressed in astrocytes, in satellite cells and in non-myelinating Schwann cells

IHC, WB (confirmed by recombinant protein). A dilution of 1 : 300 to 1 : 2000 is recommended. The optimal dilution should be determined by the end user.

12 months after reconstitution

1. Feinstein D.L, et al. J. Neurosci. Res. 32:1-14(1992)
2. Condorelli D.F, et al. J. Neurosci. Res. 56:219-228(1999)

A synthetic peptide from aa region 250-300 of rat GFAP conjugated to an immunogenic carrier protein was used as the antigen. The peptide is homologous in mouse and rat.

http://www.uniprot.org/uniprot/P47819
http://www.uniprot.org/uniprot/P03995
http://www.uniprot.org/uniprot/P141365

Polyclonal

Lyophilised